Literature DB >> 23477855

Computerized range of motion analysis following dual mobility total hip arthroplasty, traditional total hip arthroplasty, and hip resurfacing.

Gregory G Klingenstein1, Alyssa M Yeager, Joseph D Lipman, Geoffrey H Westrich.   

Abstract

Newer arthroplasty designs claim to provide superior range of motion (ROM) and greater stability than their predecessors. However, there is no way to compare ROM of implant systems in an equivalent anatomical environment in a clinical setting. This study used computer-aided design to compare ROM after hip resurfacing, 28 mm THA, 36 mm THA, and anatomic dual mobility (ADM) THA in 3D models of 5 cadaver pelvises. ROM to impingement was then tested in 10 different motions and a one-way ANOVA was used to compare results. The hip resurfacing resulted in restricted ROM compared to the other 3 models in all motions except adduction. The ADM, 36 mm, and 28 mm THA resulted in similar ROM. Dual mobility constructs provide comparable ROM in patients where large head THA is not appropriate.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  dual mobility; hip resurfacing; range of motion; total hip arthroplasty

Mesh:

Year:  2013        PMID: 23477855     DOI: 10.1016/j.arth.2012.08.017

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  2 in total

1.  Does dual-mobility cup geometry affect posterior horizontal dislocation distance?

Authors:  Christopher Heffernan; Samik Banerjee; Jim Nevelos; James Macintyre; Kimona Issa; David C Markel; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2014-01-24       Impact factor: 4.176

2.  In Revision THA, Is the Re-revision Risk for Dislocation and Aseptic Causes Greater in Dual-mobility Constructs or Large Femoral Head Bearings? A Study from the Australian Orthopaedic Association National Joint Replacement Registry.

Authors:  Wayne Hoskins; Sophia Rainbird; Chelsea Dyer; Stephen E Graves; Roger Bingham
Journal:  Clin Orthop Relat Res       Date:  2022-01-03       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.